Meeting
2022 ASCO Annual Meeting
Subcutaneous epcoritamab + R-DHAX/C in patients (pts) with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) eligible for autologous stem cell transplant (ASCT): Preliminary phase 1/2 results.
Authors
Pau Abrisqueta
Vall d'Hebron University Hospital, Barcelona, Spain
Pau Abrisqueta , Lorenzo Falchi , Tycel Jovelle Phillips , Sven De Vos , Marcel Nijland , Fritz Offner , Irina Bykhovski , Jun Wu , Liwei Wang , Ali Rana , Raul Cordoba
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies
Sub Track
Cell Therapy, Bispecific Antibodies, and Autologous Stem Cell Transplantation for NHL, HL, or CLL
Clinical Trial Registration Number
NCT04663347
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 7528)
DOI
10.1200/JCO.2022.40.16_suppl.7528
Abstract #
7528
Poster Bd #
182
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Epcoritamab + R-DHAX/C in transplant-eligible patients (pts) with high-risk relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
First Author: Yasmin Karimi
Poster
2022 ASCO Annual Meeting
Epcoritamab (epco) with gemcitabine + oxaliplatin (GemOx) in patients (pts) with relapsed or refractory (R/R) diffuse large B‑cell lymphoma (DLBCL) ineligible for autologous stem cell transplant (ASCT) induces high response rate even in pts failing CAR T therapy.
First Author: Joshua Brody
Poster
2021 ASCO Annual Meeting
Phase 3 trial (GCT3013-05) of epcoritamab versus standard of care in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
First Author: Catherine Thieblemont
